tetano
Editor, Senior Moderator
Int J Biol Macromol. 2018 Aug 9. pii: S0141-8130(18)32896-4. doi: 10.1016/j.ijbiomac.2018.08.047. [Epub ahead of print]
[h=1]Berberine-piperazine conjugates as potent influenza neuraminidase blocker.[/h] Enkhtaivan G[SUP]1[/SUP], Kim DH[SUP]1[/SUP], Park GS[SUP]1[/SUP], Pandurangan M[SUP]1[/SUP], Nicholas DA[SUP]2[/SUP], Moon SH[SUP]3[/SUP], Kadam AA[SUP]4[/SUP], Patel RV[SUP]5[/SUP], Shin HS[SUP]5[/SUP], Mistry BM[SUP]6[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] In these studies, we analyzed substituted piperazine based berberine analogs conjugated through a pentyloxy side chain for their in vitro and in silico biological effects. All the final analogs were screened for their in vitro antiviral action against a collection of different influenza virus strains using the CPE assay and SRB assay. Moreover, their cytotoxicity towards non-cancer cell lines was examined employing Madin-Darby canine kidney (MDCK) cell lines. The anti-influenza activities of berberine-piperazine derivatives (BPD) were evaluated in the range from 35.16 μg/mL to 90.25 μg/mL of the IC[SUB]50[/SUB]s along with cytotoxicity level which was observed in the range 44.8 μg/mL to 3890.6 μg/mL of CC[SUB]50[/SUB]s towards MDCK cells. In an effort to know the mechanism of action of BPD1-BPD23, results of Neuraminidase inhibition assay and Molecular docking studies carried out against neuraminidase as the target enzyme revealed that titled compounds are potential neuraminidase inhibitors that merge to the active site of neuraminidase, with moderate to high binding energy.
[h=4]KEYWORDS:[/h] Berberine-piperazine derivatives; Docking; Influenza virus; Neuraminidase inhibitors
PMID: 30099043 DOI: 10.1016/j.ijbiomac.2018.08.047
[h=1]Berberine-piperazine conjugates as potent influenza neuraminidase blocker.[/h] Enkhtaivan G[SUP]1[/SUP], Kim DH[SUP]1[/SUP], Park GS[SUP]1[/SUP], Pandurangan M[SUP]1[/SUP], Nicholas DA[SUP]2[/SUP], Moon SH[SUP]3[/SUP], Kadam AA[SUP]4[/SUP], Patel RV[SUP]5[/SUP], Shin HS[SUP]5[/SUP], Mistry BM[SUP]6[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] In these studies, we analyzed substituted piperazine based berberine analogs conjugated through a pentyloxy side chain for their in vitro and in silico biological effects. All the final analogs were screened for their in vitro antiviral action against a collection of different influenza virus strains using the CPE assay and SRB assay. Moreover, their cytotoxicity towards non-cancer cell lines was examined employing Madin-Darby canine kidney (MDCK) cell lines. The anti-influenza activities of berberine-piperazine derivatives (BPD) were evaluated in the range from 35.16 μg/mL to 90.25 μg/mL of the IC[SUB]50[/SUB]s along with cytotoxicity level which was observed in the range 44.8 μg/mL to 3890.6 μg/mL of CC[SUB]50[/SUB]s towards MDCK cells. In an effort to know the mechanism of action of BPD1-BPD23, results of Neuraminidase inhibition assay and Molecular docking studies carried out against neuraminidase as the target enzyme revealed that titled compounds are potential neuraminidase inhibitors that merge to the active site of neuraminidase, with moderate to high binding energy.
[h=4]KEYWORDS:[/h] Berberine-piperazine derivatives; Docking; Influenza virus; Neuraminidase inhibitors
PMID: 30099043 DOI: 10.1016/j.ijbiomac.2018.08.047